Form 4: Oncotelic Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Seymour Howard Fein, CRO/CMO of Oncotelic Therapeutics, Inc., received 250 shares of common stock on July 10, 2026.
Summary
- Grant/award: acquired 250 Restricted stock Units on July 10, 2026; holds 250 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Seymour Howard Fein — Officer (CRO/CMO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-10 | Grant/award | Restricted stock Units | 250 | — | — | 250 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-10 | Grant/award (250 shares) |
Keywords
insider transaction, Form 4, OTLC, Oncotelic Therapeutics, Inc., neutral, Seymour Howard Fein
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.